HPGC Renmintongtai Pharmaceutical Corporation (SHA:600829)
China · Delayed Price · Currency is CNY 8.71
+0.10 (1.16%)
Oct 23, 2026, 3:00 PM CST
SHA:600829 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 10,599 | 10,339 | 10,007 | 10,349 | 9,598 | 9,277 |
Other Revenue | 39.52 | 39.52 | 41.1 | 40.7 | 43.11 | 37.82 |
| 10,639 | 10,379 | 10,048 | 10,390 | 9,641 | 9,315 | |
Revenue Growth | 4.14% | 3.29% | -3.29% | 7.77% | 3.50% | 16.36% |
Cost of Revenue | 9,751 | 9,532 | 9,190 | 9,404 | 8,734 | 8,331 |
Gross Profit | 887.54 | 847.01 | 858.46 | 986.12 | 907.13 | 984.54 |
Selling, General & Admin | 545.76 | 528.96 | 506.23 | 519.16 | 506.2 | 544.46 |
Other Operating Expenses | 39.41 | 32.3 | 33.13 | 30.43 | 29 | 17.81 |
Operating Expenses | 623.89 | 621.23 | 558.6 | 574.43 | 524.12 | 571.43 |
Operating Income | 263.65 | 225.78 | 299.86 | 411.68 | 383.01 | 413.11 |
Interest Expense | -23.79 | -24.48 | -28.29 | -27.23 | -44.42 | -50.32 |
Interest & Investment Income | 2.8 | 4.05 | 21.65 | 17.82 | 13.34 | 5.94 |
Other Non Operating Income (Expenses) | -7.26 | -9.08 | -7.4 | -9.11 | -11.9 | -5.8 |
EBT Excluding Unusual Items | 235.39 | 196.28 | 285.83 | 393.16 | 340.02 | 362.93 |
Gain (Loss) on Sale of Investments | -0.95 | -0.95 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.35 | -0.44 | 0.23 | -0.35 | -0.41 | 0.05 |
Asset Writedown | -2.26 | -2.26 | -2.15 | -0.81 | -0.25 | -1.92 |
Legal Settlements | - | - | - | - | - | -0.29 |
Other Unusual Items | -7.36 | -3.08 | 5.15 | 1.38 | 6.2 | -2.16 |
Pretax Income | 224.47 | 189.54 | 289.06 | 393.39 | 345.56 | 358.6 |
Income Tax Expense | 65.89 | 55.7 | 75.79 | 101.14 | 81.04 | 82.09 |
Earnings From Continuing Operations | 158.58 | 133.84 | 213.27 | 292.25 | 264.51 | 276.51 |
Minority Interest in Earnings | - | -0 | 0 | -0.09 | -0.03 | 0.78 |
Net Income | 158.58 | 133.84 | 213.27 | 292.16 | 264.48 | 277.3 |
Net Income to Common | 158.58 | 133.84 | 213.27 | 292.16 | 264.48 | 277.3 |
Net Income Growth | 33.10% | -37.24% | -27.00% | 10.47% | -4.62% | 90.89% |
Shares Outstanding (Basic) | 580 | 580 | 580 | 580 | 580 | 580 |
Shares Outstanding (Diluted) | 580 | 580 | 580 | 580 | 580 | 580 |
Shares Change | -0.01% | 0.01% | -0.01% | 0.01% | -0.00% | -0.20% |
EPS (Basic) | 0.27 | 0.23 | 0.37 | 0.50 | 0.46 | 0.48 |
EPS (Diluted) | 0.27 | 0.23 | 0.37 | 0.50 | 0.46 | 0.48 |
EPS Growth | 33.11% | -37.25% | -27.00% | 10.46% | -4.62% | 91.28% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 155.06 | 282.82 | 107.39 | 309.5 | 300.91 | -245.24 |
Free Cash Flow Per Share | 0.27 | 0.49 | 0.18 | 0.53 | 0.52 | -0.42 |
Dividend Per Share | - | - | - | 0.144 | - | - |
Dividend Growth | - | - | - | 20.00% | - | - |
Gross Margin | 8.34% | 8.16% | 8.54% | 9.49% | 9.41% | 10.57% |
Operating Margin | 2.48% | 2.17% | 2.98% | 3.96% | 3.97% | 4.44% |
Profit Margin | 1.49% | 1.29% | 2.12% | 2.81% | 2.74% | 2.98% |
Free Cash Flow Margin | 1.46% | 2.73% | 1.07% | 2.98% | 3.12% | -2.63% |
EBITDA | 277.76 | 242.58 | 320.25 | 431.76 | 403.9 | 436.37 |
EBITDA Margin | 2.61% | 2.34% | 3.19% | 4.16% | 4.19% | 4.68% |
D&A For EBITDA | 14.11 | 16.8 | 20.39 | 20.08 | 20.89 | 23.26 |
EBIT | 263.65 | 225.78 | 299.86 | 411.68 | 383.01 | 413.11 |
EBIT Margin | 2.48% | 2.17% | 2.98% | 3.96% | 3.97% | 4.44% |
Effective Tax Rate | 29.35% | 29.39% | 26.22% | 25.71% | 23.45% | 22.89% |
Revenue as Reported | 10,639 | 10,379 | 10,048 | 10,390 | 9,641 | 9,315 |
Advertising Expenses | - | 9.04 | 9.1 | 5.86 | 5.45 | 8.91 |